Metrics as of 10/13/2026, 06:53 PM (Berlin time), refresh in progress.
Candel Therapeutics Stock
Candel Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Paul-Peter Tak
- Employees
- 55
- Market cap
- $679 M
- IPO
- 27/07/2021
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III…
Candel Therapeutics stock: price history
1D
-5.2%
1W
-6.1%
1M
-12.1%
6M
+81.8%
YTD
+64.1%
1Y
+43.3%
2Y
+54.0%
5Y
-13.7%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~13% weaker price swings than usual
Candel Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 02/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Candel Therapeutics is a clinical-stage biopharmaceutical company whose business model is based on the development of innovative immunotherapies for the treatment of various cancer types. The focus is on the drug candidates CAN-2409, which is in clinical trials for pancreatic, lung, and prostate cancer, and CAN-3110 for the treatment of recurrent glioblastoma. The research pipeline encompasses various stages of development from Phase I through Phase III to validate the therapeutic efficacy of its approaches.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Candel Therapeutics
Analyst assessment of Candel Therapeutics
PRICE TARGET LOW
US$22.00
CONSENSUS
US$22.50
MEDIAN
US$22.50
PRICE TARGET HIGH
US$23.00
0
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 21/09/2026
Candel Therapeutics stock metrics
P/E
-6.57
P/B
5.45
EV/EBITDA
-6.34
RETURN ON EQUITY
-30.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.39
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.5%
FLOAT SHARES
56,808,614
AVG. DAILY VOLUME (30D)
1,104,024
Insider transactions (SEC)
Tak Paul Peter
Tak Paul Peter
Tak Paul Peter
Tyagarajan Seshu
Barone Francesca
Institutional holders
Comparable stocks
Frequently asked questions about Candel Therapeutics stock
What does Candel Therapeutics do?
Candel Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Paul-Peter Tak, the company employs around 55 people.
The IPO was on 27/07/2021; the stock trades on NASDAQ under the ticker CADL.
What do analysts say about Candel Therapeutics stock?
10 analysts rate the stock, the consensus is Buy (as of 21/09/2026).
The average price target is US$22.50, ranging from US$22.00 to US$23.00, with a median of US$22.50.
This is an external assessment, not a statement by Market Jury.
When does Candel Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -13% stronger than usual.
Does Candel Therapeutics pay a dividend?
No, Candel Therapeutics currently does not pay a dividend.
Which stocks are comparable to Candel Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Candel Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Candel Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.